Uromigos Live 2023: Current and Future Status of Radioligand Therapy in Prostate Cancer

During the second-annual Uromigos Live & Unplugged event, Brian Rini, MD, FASCO; Michael Morris, MD; Rana McKay, MD; Tanya Dorff, MD; and Neeraj Agarwal, MD, discuss and deliberate on new data related to radioligand therapies in prostate cancer, including a recap of the VISION trial data and an in-depth look at the PSMAfore trial data, as well as how current practice patterns should be altered as a result of new understandings.

The panel then goes over the PSMA-directed radioligand therapies expected in multiple indications within the next several years.

View the first prostate cancer session of the day on PARP inhibitors.